Status:
COMPLETED
Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines
Lead Sponsor:
Catholic Kwandong University
Collaborating Sponsors:
Korea University Guro Hospital
Conditions:
Immune Response
Safety
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The goal is to evaluate the immunogenicity and safety of coadministration of a bivalent BA.4/BA.5-adapted COVID-19 booster vaccine, and influenza vaccine among healthy adults during 2022-23 season.
Detailed Description
This was an open-label, non-randomized clinical trial conducted at the International St. Mary's Hospital in Incheon, South Korea. This study included two study groups: Concomitant administration of bi...
Eligibility Criteria
Inclusion
- who agreed to receive both bivalent booster COVID-19 vaccine and influenza vaccine
- Only individuals who had passed at least 3 months after the last confirmation of SARS-CoV-2 infection and/or the third dose of COVID-19 vaccination
Exclusion
- Individuals with a contraindication to any of the vaccine compounds were excluded from the study
Key Trial Info
Start Date :
October 12 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 15 2023
Estimated Enrollment :
154 Patients enrolled
Trial Details
Trial ID
NCT05970887
Start Date
October 12 2022
End Date
December 15 2023
Last Update
March 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
International St. Mary's hospital
Incheon, Seo-gu, South Korea, 22711